title: Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
abstract: The discovery and clinical development of heat shock protein 90 (Hsp90) inhibitors continue to progress. A number of Hsp90 inhibitors are in clinical trials, and preclinical discoveries of new chemotypes that bind to distinct regions in the protein as well as isoform selective compounds are active areas of research. This review will highlight progress in the field since 2010.
authors.affiliation: Department of Chemistry and Biochemistry, Sokol Institute for Pharmaceutical Life Sciences, Montclair State University , Montclair, New Jersey 07043, United States.
authors.forename: Rohit
authors.initials: R
authors.lastname: Bhat
authors.forename: Sreedhar R
authors.initials: SR
authors.lastname: Tummalapalli
authors.forename: David P
authors.initials: DP
authors.lastname: Rotella
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D016227:Benzoquinones / Q000494:pharmacology; D015195:Drug Design; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D047029:Lactams, Macrocyclic / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000494:pharmacology; D020033:Protein Isoforms / Q000378:metabolism / Q000502:physiology; D051381:Rats; D016875:tau Proteins / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D018696:Neuroprotective Agents; D020033:Protein Isoforms; D016875:tau Proteins; C001277:geldanamycin